Minocycline with Aspirin: An Approach to Attenuate Diabetic Nephropathy in Rats

REFERENCES

• Atkins RC. The epidemiology of chronic kidney disease. Kidney Int. 2005;67:S14–S18.
   Google Scholar
• Leehey DJ. Hemodialysis in the diabetic patient with end-stage renal disease. Ren Fail. 1994;16(5):547–553.
   Web of Science ®Google Scholar
• Hostetter TH. Hypertrophy and hyperfunction of the diabetic kidney. J Clin Invest. 2001;107:161–162.
   Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433–442.
   PubMed Web of Science ®Google Scholar
• Williams ME, Tuttle KR. The next generation of diabetic nephropathy therapies: An update. Adv Chronic Kidney Dis. 2005;12:212–222.
   PubMed Web of Science ®Google Scholar
• Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int. 1994;45(2):612–622.
   PubMed Web of Science ®Google Scholar
• McLennan SV, Kelly DJ, Cox AJ, et al. Decreased matrix degradation in diabetic nephropathy: Effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia. 2002;45(2):268–275.
   Google Scholar
• Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: Structures, evolution, and diversification. FASEB J. 1998;12:1075–1095.
   Google Scholar
• Yurchenko PD, Schittney JC. Molecular architecture of the basement membrane. FASEB J. 1990;4:1577–1590.
   PubMed Web of Science ®Google Scholar
• Petitclerc E, Boutaud A, Prestayko A, New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem. 2000;275(11): 8051–8061.
   Google Scholar
• Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145–2154.
   PubMed Web of Science ®Google Scholar
• Matresian LM. The matrix-degrading metalloproteinases. Bioassays. 1992;14:455–463.
   Google Scholar
• Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6(6): 480–498.
   PubMed Web of Science ®Google Scholar
• Ahuja TS. Doxycycline decreases proteinuria in glomerulonephritis. Am J Kidney Dis. 2003;42:376–380.
   PubMed Web of Science ®Google Scholar
• Bhatt LK, Veeranjaneyulu A. Minocycline with aspirin: A therapeutic approach in the treatment of diabetic neuropathy. Neurol Sci. 2010 [Epub ahead of print] PMID: 20213226.
   Google Scholar
• Bhatt LK, Veeranjaneyulu A. Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats. Am J Transl Res. 2010;2(2):181–189.
   Google Scholar
• O'Connor AS, Schelling JR. Diabetes and the kidney. Am J Kidney Dis. 2005;46:766–773.
   PubMed Web of Science ®Google Scholar
• Kexin XU, Shukun HOU, Zhijun DU. Prognostic value of matrix metalloproteinase-2 and tissue inhibitor of metall- oproteinase-2 in bladder carcinoma. Chinese Med J. 2002; 115(5):743–745.
   Google Scholar
• Suzuki D. Metalloproteinases in the pathogenesis of diabetic nephropathy. Nephron. 1998;80(2):125–133.
   Google Scholar
• Vlassara H, Striker LJ, Teichberg S. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA. 1994;91:11704 –11708.
   PubMed Web of Science ®Google Scholar
• Senatorski G, Paczek L, Sulowicz W. Urine activity of cathepsin B, collagenase and urine excretion of TGF-beta 1 and fibronectin in membranous glomerulonephritis. Res Exp Med (Berl). 1998;198:199–206.
   Google Scholar
• Zaoui P, Cantin JF, Alimardani-Bessette M. Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions. Diabetes Metab. 2000;26(suppl. 4):25–29.
   Google Scholar
• Fogo AB. Current concepts in glomerulosclerosis. Am J Kidney Dis. 1999;34(5):LIV–LVI.
   Google Scholar
• Kurogi Y. Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev. 2003;23:15–31.
   PubMedGoogle Scholar
• Ziyadeh FN. Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int. 1993;43: 114–120.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Anderson S. The interrelationships among filtration surface area, blood pressure, and chronic renal disease. J Cardiovasc Pharmacol. 1992;19(suppl. 6):S1–S7.
   PubMedGoogle Scholar
• McMillan JI, Riordan JW, Couser WG. Characterization of aglomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest. 1996;97: 1094–1101.
   PubMedGoogle Scholar
• Ebihara I, Nakamura T, Shimada N, Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1998;32:544–550.
   PubMed Web of Science ®Google Scholar
• Steinmann-Niggli K, Ziswiler R, Kung M, Marti HP. Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol. 1998;9:397–407.
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Tsuruoko S, Fujimura A. Effect of enalapril on diabetic nephropathy in OLETF rats: The role of an anti-oxidative action in its protective properties. Clin Exp Pharmacol Physiol. 2001;28:829–830.
   Web of Science ®Google Scholar
• Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer. Clin Cancer Res. 2003;9(2):551–554.
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963–974.
   PubMed Web of Science ®Google Scholar
• Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev. 2003; 23:117–145.
   PubMed Web of Science ®Google Scholar
• Kaito K, Urayama H, Watanabe G. Doxycycline treatment in a model of early abdominal aortic aneurysm. Surg Today. 2003;33:426–433.
   PubMed Web of Science ®Google Scholar